Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications

Y. Dauvilliers, K. Šonka, RK. Bogan, M. Partinen, R. Del Rio Villegas, N. Foldvary-Schaefer, R. Skowronski, A. Chen, J. Black, F. Skobieranda, MJ. Thorpy

. 2022 ; 36 (6) : 633-647. [pub] 20220530

Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018124
E-zdroje Online Plný text

NLK ProQuest Central od 2008-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2008-01-01 do Před 1 rokem
Psychology Database (ProQuest) od 2008-01-01 do Před 1 rokem

Odkazy

PubMed 35635687
DOI 10.1007/s40263-022-00926-0
Knihovny.cz E-zdroje

BACKGROUND: Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people with narcolepsy in a placebo-controlled, double-blind, randomized withdrawal study (NCT03030599). Additional analyses of data from this study were conducted to explore the effects of LXB on cataplexy, including the clinical course and feasibility of transition from other anticataplectics to LXB monotherapy. OBJECTIVE: The aim of these analyses was to evaluate cataplexy frequency during initiation/optimization of LXB and taper/discontinuation of prior antidepressant/anticataplectic medications. METHODS: Eligible participants (adults aged 18-70 years with narcolepsy with cataplexy) entered the study taking SXB only (group A), SXB + other anticataplectics (group B), or anticataplectic medication other than SXB (group C), or were cataplexy-treatment naive (group D). LXB was initiated/optimized during a 12-week, open-label, optimized treatment and titration period (OLOTTP). Other anticataplectics were tapered/discontinued during weeks 3-10 of OLOTTP. A 2-week stable-dose period (SDP; during which participants took a stable dose of open-label LXB) and 2-week double-blind randomized withdrawal period (during which participants were randomized to continue LXB treatment or switch to placebo) followed OLOTTP. Treatment-emergent adverse events (TEAEs) were recorded throughout the duration of the study. RESULTS: At the beginning of OLOTTP, median weekly cataplexy attacks were lower in participants taking SXB at study entry (SXB only [2.00]; SXB + other anticataplectics [0.58]) versus participants who were taking other anticataplectics (3.50) or were anticataplectic naive (5.83). Median weekly cataplexy attacks decreased during weeks 1-2 of OLOTTP in all groups. Increased cataplexy frequency was observed in participants tapering/discontinuing other anticataplectics during weeks 3-10 and was more prominent in participants taking other anticataplectics alone compared with those taking SXB plus other anticataplectics. Cataplexy frequency decreased throughout initiation/optimization in anticataplectic-naive participants. Median number of cataplexy-free days/week at the end of SDP (study week 14) was similar in all groups (6.0, 6.1, 6.0, and 6.2 in groups A, B, C, and D, respectively). During OLOTTP and SDP, TEAEs of worsening cataplexy were reported in 0%, 47.8%, 16.7%, and 2.2% of participants in groups A, B, C, and D, respectively; most TEAEs of worsening cataplexy were reported during tapering/discontinuation of other anticataplectics. CONCLUSIONS: LXB monotherapy was effective in reducing cataplexy and increasing cataplexy-free days. These results illustrate the feasibility of switching from SXB to LXB while tapering/discontinuing other anticataplectics. TRIAL REGISTRATION: A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy; https://clinicaltrials.gov/ct2/show/NCT03030599 ; clinicaltrials.gov identifier: NCT03030599.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018124
003      
CZ-PrNML
005      
20220804134555.0
007      
ta
008      
220720s2022 nz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s40263-022-00926-0 $2 doi
035    __
$a (PubMed)35635687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Dauvilliers, Yves $u Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, 80 Avenue Augustin Fliche, 34295, Montpellier, France. y-dauvilliers@chu-montpellier.fr $u University of Montpellier, INSERM Institute Neuroscience Montpellier (INM), Montpellier, France. y-dauvilliers@chu-montpellier.fr $1 https://orcid.org/0000000306836506
245    10
$a Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications / $c Y. Dauvilliers, K. Šonka, RK. Bogan, M. Partinen, R. Del Rio Villegas, N. Foldvary-Schaefer, R. Skowronski, A. Chen, J. Black, F. Skobieranda, MJ. Thorpy
520    9_
$a BACKGROUND: Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people with narcolepsy in a placebo-controlled, double-blind, randomized withdrawal study (NCT03030599). Additional analyses of data from this study were conducted to explore the effects of LXB on cataplexy, including the clinical course and feasibility of transition from other anticataplectics to LXB monotherapy. OBJECTIVE: The aim of these analyses was to evaluate cataplexy frequency during initiation/optimization of LXB and taper/discontinuation of prior antidepressant/anticataplectic medications. METHODS: Eligible participants (adults aged 18-70 years with narcolepsy with cataplexy) entered the study taking SXB only (group A), SXB + other anticataplectics (group B), or anticataplectic medication other than SXB (group C), or were cataplexy-treatment naive (group D). LXB was initiated/optimized during a 12-week, open-label, optimized treatment and titration period (OLOTTP). Other anticataplectics were tapered/discontinued during weeks 3-10 of OLOTTP. A 2-week stable-dose period (SDP; during which participants took a stable dose of open-label LXB) and 2-week double-blind randomized withdrawal period (during which participants were randomized to continue LXB treatment or switch to placebo) followed OLOTTP. Treatment-emergent adverse events (TEAEs) were recorded throughout the duration of the study. RESULTS: At the beginning of OLOTTP, median weekly cataplexy attacks were lower in participants taking SXB at study entry (SXB only [2.00]; SXB + other anticataplectics [0.58]) versus participants who were taking other anticataplectics (3.50) or were anticataplectic naive (5.83). Median weekly cataplexy attacks decreased during weeks 1-2 of OLOTTP in all groups. Increased cataplexy frequency was observed in participants tapering/discontinuing other anticataplectics during weeks 3-10 and was more prominent in participants taking other anticataplectics alone compared with those taking SXB plus other anticataplectics. Cataplexy frequency decreased throughout initiation/optimization in anticataplectic-naive participants. Median number of cataplexy-free days/week at the end of SDP (study week 14) was similar in all groups (6.0, 6.1, 6.0, and 6.2 in groups A, B, C, and D, respectively). During OLOTTP and SDP, TEAEs of worsening cataplexy were reported in 0%, 47.8%, 16.7%, and 2.2% of participants in groups A, B, C, and D, respectively; most TEAEs of worsening cataplexy were reported during tapering/discontinuation of other anticataplectics. CONCLUSIONS: LXB monotherapy was effective in reducing cataplexy and increasing cataplexy-free days. These results illustrate the feasibility of switching from SXB to LXB while tapering/discontinuing other anticataplectics. TRIAL REGISTRATION: A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy; https://clinicaltrials.gov/ct2/show/NCT03030599 ; clinicaltrials.gov identifier: NCT03030599.
650    _2
$a dospělí $7 D000328
650    12
$a kataplexie $x farmakoterapie $7 D002385
650    12
$a poruchy nadměrné spavosti $x farmakoterapie $7 D006970
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé $7 D006801
650    12
$a narkolepsie $x chemicky indukované $x farmakoterapie $7 D009290
650    12
$a oxybát sodný $x škodlivé účinky $7 D012978
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Šonka, Karel $u Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Bogan, Richard K $u University of South Carolina School of Medicine, Columbia, SC, USA
700    1_
$a Partinen, Markku $u Helsinki Sleep Clinic, Terveystalo Healthcare, Helsinki, Finland $u Department of Clinical Neurosciences, University of Helsinki, Helsinki, Finland
700    1_
$a Del Rio Villegas, Rafael $u Neurophysiology and Sleep Disorders Unit, Vithas Hospitals, Madrid, Spain
700    1_
$a Foldvary-Schaefer, Nancy $u Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Skowronski, Roman $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Chen, Abby $u Jazz Pharmaceuticals, Palo Alto, CA, USA
700    1_
$a Black, Jed $u Jazz Pharmaceuticals, Palo Alto, CA, USA $u Stanford University Center for Sleep Science and Medicine, Redwood City, CA, USA
700    1_
$a Skobieranda, Franck $u Jazz Pharmaceuticals, Philadelphia, PA, USA
700    1_
$a Thorpy, Michael J $u Albert Einstein College of Medicine, Bronx, NY, USA
773    0_
$w MED00001186 $t CNS drugs $x 1179-1934 $g Roč. 36, č. 6 (2022), s. 633-647
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35635687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134549 $b ABA008
999    __
$a ok $b bmc $g 1821951 $s 1169367
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 36 $c 6 $d 633-647 $e 20220530 $i 1179-1934 $m CNS drugs $n CNS Drugs $x MED00001186
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace